Micropep Technologies and Corteva (CTVA) announced a multi-year research and development collaboration through Corteva Catalyst. The partnership aims to co-develop next-generation peptide-based biocontrol solutions, including biofungicides and disease control products. Corteva will conduct joint research with Micropep scientists and will hold exclusive rights to apply these peptides globally across biocontrol and biofungicide applications. The agreement marks the first major industry validation of Micropep’s Krisalix artificial intelligence platform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva price target raised to $92 from $80 at Jefferies
- Corteva Positioned for Growth: Buy Rating Backed by Market Resilience and Strategic Advantages
- Corteva upgraded to Positive from Negative view at BWG Global
- FMC, Corteva Agriscience collaborate on fluindapyr fungicide technology
- Trump Trade: Trump considers 50% tariff on EU, 25% on iPhones